TMCI - Treace Medical Concepts, Inc.
After hours:
| Previous close | 25.91 |
| Open | 25.83 |
| Bid | 25.11 x 1000 |
| Ask | 26.66 x 900 |
| Day's range | 25.38 - 26.07 |
| 52-week range | 13.19 - 27.97 |
| Volume | |
| Avg. volume | 361,534 |
| Market cap | 1.587B |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.85 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.40 |
Simply Wall St.Treace Medical Concepts, Inc. (NASDAQ:TMCI) is largely controlled by institutional shareholders who own 58% of the company
Key Insights Given the large stake in the stock by institutions, Treace Medical Concepts' stock price might be...
GlobeNewswireTreace Medical Concepts to Acquire Technology Enabling Patient Specific Instrumentation for Foot and Ankle Surgeries
PONTE VEDRA, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it has signed an asset purchase agreement to acquire certain assets of MIOS Marketing, LLC d/b/a RedPoint Medical3D (“RPM-3D”), a medical technology company offering pre-operative planning and patient-specific guides desi
- Simply Wall St.
Calculating The Fair Value Of Treace Medical Concepts, Inc. (NASDAQ:TMCI)
Key Insights Treace Medical Concepts' estimated fair value is US$26.10 based on 2 Stage Free Cash Flow to Equity...
ZacksTreace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 0% and 6.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Treace Medical Concepts Reports First Quarter 2023 Financial Results
PONTE VEDRA, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2023. Recent Highlights: Revenue of $42.2 million in the first quarter of 2023, a 45% increase over the same period last year.Blended average revenue per Lapiplasty® proced
- GlobeNewswire
Treace Announces Participation in the Bank of America 2023 Healthcare Conference
PONTE VEDRA, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Bank of America 2023 Healthcare Confe
- GlobeNewswire
Treace to Report First Quarter 2023 Financial Results on May 8, 2023
PONTE VEDRA, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Monday, May 8, 2023. Company management will host a conference call to discuss financia
- GlobeNewswire
Treace Medical Expands Market Leading Global IP Portfolio For Bunion And Related Deformities
PONTE VEDRA, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), is pleased to announce the continuing rapid growth of its global patent portfolio. In 2023, Treace has filed 15 new United States patent applications and the United States Patent and Trademark Office (USPTO) has granted to the Company 7 util
- Simply Wall St.
Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) P/S Is On The Mark
With a price-to-sales (or "P/S") ratio of 11.2x Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) may be sending very...
ZacksTreace Medical Concepts (TMCI) Surges 7.6%: Is This an Indication of Further Gains?
Treace Medical Concepts (TMCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- GlobeNewswire
Treace Publishes Inaugural ESG Report
PONTE VEDRA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today published its inaugural Environmental, Social and Governance (ESG) report. This report highlights the Company’s strategic and ESG-related initiatives from the past year, including: Advancing the Company’s mission to improve surgical ou
Motley FoolWhy Treace Medical Concepts' Shares Rose Wednesday
Shares of Treace Medical Concepts (NASDAQ: TMCI) were up 21% as of 3 p.m. EST Wednesday afternoon. The orthopedic medical device company's shares rose after it reported fourth-quarter earnings after the markets closed on Tuesday. Treace makes Lapiplasty surgery kits, which orthopedic surgeons use to perform minimally invasive surgery on bunions.
- GlobeNewswire
Treace Medical Concepts Reports Fourth Quarter and Full Year 2022 Financial Results
PONTE VEDRA, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequen
- GlobeNewswire
Treace Medical Announces Settlement of Lawsuit Against Fusion Orthopedics
PONTE VEDRA, Fla., March 03, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) jointly announces with Fusion Orthopedics, LLC (“Fusion Orthopedics”) that they have reached an amicable resolution of the litigation between the parties. Treace Medical filed the lawsuit on March 29, 2022 against Fusion Orthopedics i
- GlobeNewswire
Treace Medical Announces Settlement of Lawsuit Again Fusion Orthopedics
PONTE VEDRA, Fla., March 03, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) jointly announces with Fusion Orthopedics, LLC (“Fusion Orthopedics”) that they have reached an amicable resolution of the litigation between the parties. Treace Medical filed the lawsuit on March 29, 2022 against Fusion Orthopedics i
- GlobeNewswire
Treace to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
PONTE VEDRA, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Tuesday, March 7, 2023. Company management will host a conference call to
- GlobeNewswire
Treace Presents Updated ALIGN3D™ Interim Data and Latest Product Innovations at the 2023 ACFAS Annual Conference
PONTE VEDRA, Fla., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure today announced it will highlight new interim clinical data from the ALIGN3D™ study, and recent product innovations, at the 2023 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Con
- GlobeNewswire
Treace Medical Concepts, Inc. Announces Pricing of $100.0 Million Public Offering of Common Stock
PONTE VEDRA, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the pricing of an underwritten public offering of 4,761,905 shares of its common stock at a public offering price of $21.00 per share, before underwriting discounts and commissions. All o
- GlobeNewswire
Treace Medical Concepts, Inc. Announces Proposed Public Offering of Common Stock
PONTE VEDRA, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock. All of the shares of the common stock are being offered by Treace and there are no s
- Simply Wall St.
Despite currently being unprofitable, Treace Medical Concepts (NASDAQ:TMCI) has delivered a 25% return to shareholders over 1 year
It's been a soft week for Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) shares, which are down 10%. While that might be...
- GlobeNewswire
Treace Medical Concepts Provides 2022 Preliminary Unaudited Revenue
PONTE VEDRA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be in the r
- Simply Wall St.
Owning 47% shares,institutional owners seem interested in Treace Medical Concepts, Inc. (NASDAQ:TMCI),
A look at the shareholders of Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) can tell us which group is most powerful...
- GlobeNewswire
Treace to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
PONTE VEDRA, Fla., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will present the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, Janu
- GlobeNewswire
Treace Medical Announces Expansion of Its Global IP Portfolio with the Grant of Two New U.S. Patents
PONTE VEDRA, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), is pleased to announce that the United States Patent and Trademark Office has granted to the Company U.S. Patent Nos. 11,497,528 and 11,523,845. The two new patents relate to novel methods of performing bunion surgery utilizing a bone
ZacksRecent Price Trend in Treace Medical Concepts (TMCI) is Your Friend, Here's Why
Treace Medical Concepts (TMCI) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.